✨ Free AI Report
Adaptive Biotechnologies Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Adaptive Biotechnologies Corporation
Research Preview

Adaptive Biotechnologies Corporation: Business Overview, Financials & Competitive Analysis

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease through proprietary immune receptor sequenci...

Analyst-debate audio for Adaptive Biotechnologies Corporation

AskCyborg analysts argue the bull and bear cases for Adaptive Biotechnologies Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Adaptive Biotechnologies Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Adaptive delivered 46% revenue growth and achieved profitability in its MRD business, positioning itself to drive continued...

Read the full analyst-debate transcript →
Industry Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Adaptive Biotechnologies Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Adaptive Biotechnologies Corporation Overview

Pro stress-test →

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease through proprietary immune receptor sequencing and analysis that decodes T-cell and B-cell receptors to identify signatures of immune response. The company reported full-year 2025 revenue of $277.0 million, a 55% increase year-over-year, with the MRD business driving growth.

Strategic Profile

Pro stress-test →

Adaptive leverages proprietary immune receptor sequencing technology to decode the genetic information of T-cell and B-cell receptors. The company operates two business segments: clonoSEQ MRD (Minimal Residual Disease) diagnostics for blood cancers and immune medicine development, with a path to companywide profitability in 2026.

Competitive Landscape

Pro stress-test →

The biotechnology and pharmaceutical industries are characterized by intense competition, with many companies pursuing advancements in immune medicine and larger companies with greater resources potentially overshadowing its offerings. There are concerns about incoming competition in the DLBCL space, which may affect market penetration.

Industry Context

Adaptive Biotechnologies Corporation operates in Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics.

Key facts

Founded: 2009 · Headquarters: Seattle, US · Employees: ~620 · Revenue: $277.0M · Market cap: $1.4B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Adaptive Biotechnologies Corporation.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Adaptive Biotechnologies Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

LiquidBiopsyBlood-based cancer diagnostics and MRD detection→Other MRD TestingCompetitor immune profiling and diagnostics platforms→Large Pharma TCR ProgramsTCR therapy development in autoimmune disorders→

Compare Adaptive Biotechnologies Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Adaptive Biotechnologies Corporation operates in Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Clinical-Stage Biotechnology by Cyborg Score

Browse Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics research →
NEW · MCP server

Ask your AI assistant about Adaptive Biotechnologies Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Adaptive Biotechnologies Corporation and its top competitor on Cyborg Score”
“What did Adaptive Biotechnologies Corporation do this quarter?”
“Is Adaptive Biotechnologies Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Adaptive Biotechnologies Corporation do?+
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease through proprietary immune receptor sequenci...
What is Adaptive Biotechnologies Corporation's Cyborg Score?+
Adaptive Biotechnologies Corporation has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Adaptive Biotechnologies Corporation's main competitors?+
Named competitors include LiquidBiopsy, Other MRD Testing, Large Pharma TCR Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Adaptive Biotechnologies Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Adaptive Biotechnologies Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Adaptive Biotechnologies Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Clinical-stage Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Evommune, Inc.7Monte Rosa Therapeutics, Inc.7PepGen Inc.7Tectonic Therapeutic, Inc.6Adlai Nortye Ltd.6Coya Therapeutics, Inc.6Vigil Neuroscience, Inc.5Cel-Sci Corporation4Cassava Sciences, Inc.4INmune Bio Inc.Top companies in Clinical-Stage Biotechnology by Cyborg Score